

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/ Madam,

Sub: Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ICDR Regulations”)

Pursuant to Regulation 169(5) of the ICDR Regulations, please find enclosed herewith, a certificate issued by S R B C & Co LLP, Chartered Accountants, Statutory Auditors of the Company, certifying that the issuer (i.e. Company) is in compliance with Regulation 169(4) of ICDR Regulations and the relevant documents thereof are maintained by the issuer as on the date of the certificate.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**



Dinesh Lahoti
Company Secretary and Compliance Officer
ICSI Membership No.: A22471

Encl: As above

Certificate with respect to listing of equity shares allotted on conversion of warrants on preferential basis

We, S R B C & CO LLP, have verified the relevant records and documents of Sun Pharma Advanced Research Company Limited with respect to the listing of 8,426,966 equity shares allotted on conversion of warrants on preferential basis in terms of Part VI of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations") thereof and certify the following:

1. The Company has realised the 25% upfront money amounting to Rs. 1,499,999,993/- on or before July 07, 2021 against the allotment of 33,707,865 Convertible Warrants (the "Warrants") at the price of Rs. 178 per Warrant and further the Company has also realised the balance 75% allotment monies amounting to Rs. 1,124,999,961/-, from the bank account of an allottee on or before March 21, 2022 against allotment of the 8,426,966 equity shares on conversion of the 8,426,966 Warrants from an applicant of the aforesaid shares and there is no circulation of funds or mere passing of book entries in this regard.
We further confirm that the 25% upfront money received from the allottee(s) w.r.t. unexercised convertible warrants as on date, has not been adjusted towards the balance 75% allotment money of the allottee(s) or towards any other allottees.
2. Consideration of Rs. 2,624,999,954/- paid in cash, has been received from the allottee's bank account and the relevant documents thereof are maintained by Sun Pharma Advanced Research Company Limited as on the date of issue of certification.
3. The Company is in compliance with the relevant requirements of Companies Act, 2013, relevant provisions of Chapter V of ICDR Regulations viz sub-regulation (5) of Regulation 169 of Chapter V of ICDR Regulations, sub-section (6) of Section 42 of the Companies Act 2013 and Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, and relevant documents, including records of Bank Account Statements of each allottee regarding subscription money received from their respective banks accounts, are maintained by the issuer.

This certificate is to be read with the enclosed Annexure to Auditors certificate of even date.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm Registration Number: 324982E/E300003

PAUL MICHAEL
ALVARES

Digitally signed by PAUL
MICHAEL ALVARES
DN: cn=PAUL MICHAEL
ALVARES, c=IN, o=Personal,
email=paul.alvares@srb.in
Date: 2022.03.28 17:48:34 +05'30'

per Paul Alvares
Partner
Membership Number: 105754

UDIN: 22105754AFSWTP5540

Place of Signature: Pune
Date: March 28, 2022

Annexure to Auditor's Certificate

To
The Board of Directors
Sun Pharma Advanced Research Company Limited
17 B Mahal Industrial Estate,
Mahakali Caves Road, Andheri(E),
Mumbai - 400 093

1. This Report is issued in accordance with the terms of our service scope letter dated July 15, 2021 read with Master Engagement Agreement dated October 12, 2017 with Sun Pharma Advanced Research Company Limited (hereinafter the "Company").
2. In connection with the preferential issue of 62,474,082 Convertible Warrants (the "Warrants"), each convertible into, or exchangeable for, one equity share of face value of Re. 1 each at an issue price of Rs 178 each, the Company is required to obtain a report from the Statutory Auditors, with regard to receipt of consideration of specified securities in connection with the preferential issue, as required by Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations") read with listing requirements of BSE Limited and National Stock Exchange of India Limited, sub-section (6) of Section 42 of the Companies Act 2013 and Rule 14 of the Companies (Prospectus and Allotment of Securities), Rules, 2014 for the purpose of submission to BSE Limited and National Stock Exchange of India Limited.
3. The accompanying statement contains details of receipt of consideration against allotment of specified securities as required by sub para (4) of Regulation 169 of Part VI of Chapter V of the ICDR Regulations and Companies Act 2013, in respect of the preferential issue (the "Statement"), which we have initialed for identification purposes only.

Managements' Responsibility for the Statement

4. The preparation of the accompanying Statement is the responsibility of Management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes designing, implementing and maintaining internal control relevant to the preparation and presentation of the Statement, and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.
5. The Management is also responsible for ensuring:
 - a) the consideration of specified securities is received from respective allottee's bank account;
 - b) the consideration of specified securities is received from the bank account of the person whose name appears first in the application;
 - c) maintenance of relevant records in relation to point (a) and (b) above; and
 - d) compliance with the requirements of the ICDR Regulations and the Companies Act, 2013 and relevant rules thereunder.

Auditor's Responsibility

6. Pursuant to the requirements of sub para (5) of Regulation 169 of Part VI of Chapter V of the ICDR Regulations, it is our responsibility to provide limited assurance as to whether the details provided in the Statement is in accordance with sub para (4) of Regulation 169 of Part VI of Chapter V of the ICDR Regulations and the relevant documents thereof are maintained by the Company including adherence to the listing agreement with BSE Limited and National Stock Exchange of India Limited with respect to circulation of funds or mere passing of book entries as on the date of issue of the certificate.
7. The ICDR Regulations applicable to preferential issue of Warrants require many conditions which are to be complied with subsequent to the issue of warrants. This certificate does not cover those conditions.
8. We conducted our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes and the Guidance Note on Reports in Company Prospectuses (Revised 2019) both issued by the Institute of Chartered Accountants of India ("ICAI"). The Guidance Note on Reports or Certificates for Special Purposes requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.
10. A limited assurance engagement includes performing procedures to obtain sufficient appropriate evidence on the applicable criteria mentioned in paragraph 6 above. The procedures performed vary in nature, timing and extent from, and are less extent than for, a reasonable assurance. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had we performed a reasonable assurance engagement. Accordingly, we have performed the following procedures in relation to the Statement:
 - a) Obtained listing of allottees together with 25% upfront amount received from each applicant from the management.
 - b) With respect to 25% upfront money received by the Company, obtained bank statement of the Company for the period June 01, 2021 to July 07, 2021 and traced the name of the person and the amounts appearing in the Statement to the bank statements. We have relied on the information obtained from the management in this regard and have not performed any independent procedures;
 - c) With respect to balance 75% money to be received by the Company, obtained listing of allottees together with amount to be received from the applicant from management.
 - d) With respect to 75% money received by the Company, obtained bank statement of the Company from the period from March 21, 2022 to March 28, 2022 and traced the name of the person and the amounts appearing in the Statement to the bank statements. We have relied on the information obtained from management in this regard and have not performed any independent procedures;
 - e) With respect to allotment of Warrants, obtained the copy of the resolution passed by Securities Allotment Committee in its meeting held on July 08, 2021 approving the allotment of 62,474,082 convertibles warrants to respective allottee's;
 - f) With respect to allotment of 8,426,966 equity of face value of Re. 1 each to an allottee, obtained the copy of resolution passed by Securities Allotment Committee in its meeting held on March 21, 2022 approving the allotment of 8,426,966 equity shares of face value of Re.1 each to an allottee; and
 - g) Conducted relevant management inquiries and obtained necessary representation.

Conclusion

11. Based on our examination as above, and the information, explanations and management representations provided to us, nothing has come to our attention that causes us to believe that there is circulation of funds or mere passing of book entries; the details provided in the Statement are not in accordance with the requirements of sub para (4) of Regulation 169 of Part VI of Chapter V of the ICDR Regulations and the relevant documents thereof are not maintained by the Company as on the date of issue of certificate.

Restriction on Use

12. This report is addressed to and provided to the Board of Directors of the Company solely for the purpose of further submission to BSE Limited and National Stock Exchange of India Limited in connection with the preferential issue, as required by the ICDR Regulations and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing. We have no responsibility to update this report for events and circumstances occurring after the date of this report.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

PAUL MICHAEL
ALVARES

Digitally signed by PAUL
MICHAEL ALVARES
DN: cn=PAUL MICHAEL
ALVARES, c=IN, o=Personal,
email=paul.alvares@srb.in
Date: 2022.03.28 17:49:16 +05'30'

per Paul Alvares

Partner

Membership Number: 105754

UDIN: 22105754AFSWTP5540

Place of Signature: Pune

Date: March 28, 2022

Sun Pharma Advanced Research Company Limited

Statement of Funds Received (the "Statement")

Sr. No.	Name of the Allottee's ('Allottee's')	Number of warrants allotted on July 08, 2021	25% upfront money received on or before July 07, 2021 (In Rs.)	Balance 75% of allotment money received on or before March 21, 2022 (In Rs.)	Balance 75% of allotment money pending to be received as on March 21, 2022 (In Rs.)	Number of shares of face value of Re. 1 each allotted	Date of Allotment of equity shares upon conversion of warrants
1	Dilip Shantilal Shanghvi	3,37,07,865	1,49,99,99,993	1,12,49,99,961	3,37,50,00,017	84,26,966	21-03-2022
2	Rekha Jhunjhunwala	62,92,134	27,99,99,963	-	83,99,99,889	-	
3	Enam Securities Private Limited	33,70,786	14,99,99,977	-	44,99,99,931	-	
4	ITI Holdings and Investment Private Limited	28,08,988	12,49,99,966	-	37,49,99,898	-	
5	Minosha India Limited	16,85,393	7,49,99,989	-	22,49,99,966	-	
6	University of Notre Dame DU Lac	15,38,033	6,84,42,469	-	20,53,27,406	-	
7	Abakkus Growth Fund - 1	14,04,494	6,24,99,983	18,74,99,949	-	14,04,494	25-08-2021
8	Cohesion MK Best Ideas Sub-Trust	14,04,494	6,24,99,983	-	18,74,99,949	-	
9	Winro Commercial (India) Limited	12,92,134	5,74,99,963	-	17,24,99,889	-	
10	Amal N. Parikh	11,23,595	4,99,99,978	-	14,99,99,933	-	
11	Singularity Holdings Limited	9,55,056	4,24,99,992	-	12,74,99,976	-	
12	Trishakti Power Holdings Private Limited	7,02,247	3,12,49,992	-	9,37,49,975	-	
13	Arun Nahar	5,61,797	2,49,99,967	-	7,49,99,900	-	
14	Fortune Financial & Equities Services Private Limited	5,61,797	2,49,99,967	-	7,49,99,900	-	
15	Jash Choraria	5,61,797	2,49,99,967	-	7,49,99,900	-	
16	Ketan Chhotalal Sheth	5,61,797	2,49,99,967	-	7,49,99,900	-	
17	Pivotal Enterprises Private Limited	5,61,797	2,49,99,967	-	7,49,99,900	-	
18	Dovetail India Fund Class 11 Shares	5,33,707	2,37,49,962	-	7,12,49,885	-	
19	The Ram Fund, L.P.	4,74,269	2,11,04,971	-	6,33,14,912	-	
20	GP Emerging Markets Strategies, L.P.	4,41,123	1,96,29,974	-	5,88,89,921	-	
21	Sanjana Cryogenic Storages Limited	3,37,078	1,49,99,971	-	4,49,99,913	-	
22	Geecee Ventures Limited	2,80,898	1,24,99,961	-	3,74,99,883	-	
23	Shruti Gagan Chaturvedi	2,80,898	1,24,99,961	-	3,74,99,883	-	
24	Amit Goela	2,01,123	89,49,974	-	2,68,49,921	-	
25	Massachusetts Institute of Technology	1,79,775	79,99,988	-	2,39,99,963	-	
26	Pragma Fund SPC- Equities Segregated Portfolio	1,71,235	76,19,958	-	2,28,59,873	-	
27	Avinash Sudhir Sule	1,66,292	73,99,994	-	2,21,99,982	-	
28	Nipa Sheth	1,00,561	44,74,965	-	1,34,24,894	-	
29	Utpal Sheth	1,00,561	44,74,965	-	1,34,24,894	-	
30	Ashish Maheshwari	84,269	37,49,971	-	1,12,49,912	-	
31	Dovetail India Fund - Class 6 Shares	28,089	12,49,961	-	37,49,882	-	
	Total	6,24,74,082	2,78,00,96,649	1,31,24,99,910	7,02,77,90,037	98,31,460	

Note

The Securities Allotment Committee of the Board of Directors at its meeting held on March 21, 2022 has allotted 84,26,966 equity shares of Re. 1/- each to the allottee (mentioned at Sr. No. 1 above), upon conversion of equal no. of warrants exercised for conversion by the said allottee.

All the allotment money is received by the Company in its designated bank maintained with Kotak Mahindra Bank bearing number 1945194038.

Considering the above allotment along with earlier allotment(s), the Company has till date allotted 98,31,460 equity shares against conversion of warrants exercised by the respective allottee(s) out of the total 6,24,74,082 warrants so allotted by the Company. The remaining 5,26,42,622 warrants, the respective allottees have not yet exercised their option for conversion/exchange the warrants into/for equity shares and accordingly, balance 75% money towards such remaining warrants is yet to be received. The last day for exercising the option for conversion/exchange the warrants into/for equity shares of the Company is January 07, 2023, being 18 months from the date of allotment of warrants i.e. July 08, 2021.

For Sun Pharma Advanced Research Company Limited


Dinesh Lahoti
Company Secretary
Authorised Signatory
Place : Mumbai
Date : March 28, 2022

